AGEN

Agenus Inc.

Price

chg

quotes and stock data delayed 15 minutes

Cash

$79.2M

Burn Rate (Qtr)

$47.5M

Mkt Cap

mkt cap api

52 wk hi

52 wk low

low api

high api

*cash/burn updated:

Q3 '20

Company Profile

The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Balstilimab (AGEN2034)

Recurrent/Metastatic Cervical Cancer

BLA Submission (Ph2 data)

H1 2021

Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4)

Refractory Cervical Cancer

BLA filing

H1 2021

AGEN1181 (anti-CLTA-4)

Advanced endometrial cancer

Phase 2 (Data)

AGEN-797 (Unmodified allogenic iNTKs)

Cancer

Phase 1

January 2021 (Est)

Initiation

Dec '20 Co. presentation: "Phase 1: Anticipated 2020"

Allogenic iNKTs

COVID-19

Phase 1 Trial

TBD

Update

AGEN 1777 (anti-TIGIT)

Cancer

IND Submission

AGEN1327 (anti-TIGIT)

Cancer

IND Submission

Q1 2021

Submission

Dec 2020 corp slide deck - IND Q1 2021.

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon